Novartis AG (NYSE:NVS) Shares Bought by Mosley Wealth Management

Mosley Wealth Management lifted its stake in shares of Novartis AG (NYSE:NVS) by 4.9% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 2,238 shares of the company’s stock after purchasing an additional 105 shares during the period. Mosley Wealth Management’s holdings in Novartis were worth $238,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Frazier Financial Advisors LLC acquired a new position in Novartis during the 4th quarter worth approximately $26,000. Private Ocean LLC purchased a new position in Novartis in the first quarter valued at $25,000. Richardson Financial Services Inc. acquired a new stake in Novartis in the fourth quarter valued at $26,000. New Millennium Group LLC purchased a new stake in Novartis during the 2nd quarter worth about $28,000. Finally, Clearstead Trust LLC boosted its position in shares of Novartis by 73.5% during the 1st quarter. Clearstead Trust LLC now owns 269 shares of the company’s stock worth $26,000 after acquiring an additional 114 shares in the last quarter. 13.12% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on NVS shares. Barclays upgraded shares of Novartis to a “strong sell” rating in a research report on Monday, June 24th. Jefferies Financial Group cut shares of Novartis from a “buy” rating to a “hold” rating in a research report on Tuesday. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $121.00 price objective (up previously from $119.00) on shares of Novartis in a report on Thursday. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Novartis in a research report on Friday, July 19th. One research analyst has rated the stock with a sell rating, six have given a hold rating and one has issued a strong buy rating to the stock. According to MarketBeat, Novartis presently has an average rating of “Hold” and an average price target of $118.38.

Novartis Price Performance

NVS stock traded up $0.16 on Friday, reaching $116.65. 1,151,373 shares of the company’s stock were exchanged, compared to its average volume of 1,407,379. The firm has a market cap of $238.43 billion, a PE ratio of 15.75, a P/E/G ratio of 1.77 and a beta of 0.57. Novartis AG has a twelve month low of $92.19 and a twelve month high of $120.92. The stock has a fifty day moving average of $112.66 and a 200-day moving average of $104.51. The company has a quick ratio of 0.72, a current ratio of 0.93 and a debt-to-equity ratio of 0.47.

Novartis (NYSE:NVS) last announced its quarterly earnings data on Thursday, July 18th. The company reported $1.97 EPS for the quarter, beating the consensus estimate of $1.87 by $0.10. Novartis had a net margin of 33.76% and a return on equity of 34.56%. The firm had revenue of $12.87 billion during the quarter, compared to analysts’ expectations of $12.24 billion. During the same quarter last year, the business earned $1.83 earnings per share. As a group, equities analysts predict that Novartis AG will post 7.48 EPS for the current fiscal year.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.